ARTIMPLANT INTERIM REPORT JANUARY – JUNE 2009

Västra Frölunda, Sweden, August 5, 2009

• Net revenue for the second quarter amounted to SEK 7.9 million (3.1) and for the first six months SEK 12.8 million (5.2)* • The net loss for the second quarter totaled SEK 4.1 million (6.2) and for the first six months SEK 8.6 million (12.3) • Earnings per share for the second quarter amounted to SEK -0.07 (-0.10) and for the first six months SEK -0.14 (-0.21) • Sales of Artelon® Spacer for the second quarter totaled SEK 4.7 million (2.4) and for the first six months SEK 8.2 million (3.7) • Sales of Artelon® Tissue Reinforcement for the second quarter amounted to SEK 3.1 million (0.6) and for the first six months SEK 4.4 million (1.4) • The first patient has been enrolled in a clinical investigation of treatment of osteoarthritis in the lumbar facet joints using an Artelon® implant • The first dogs in the USA underwent surgery using Artelon® CCL for cruciate ligament injuries N.B. This is a translation from Swedish. The Swedish version shall always take precedence. Artimplant will hold a telephone conference by reason of this report on August 5, 2009 at 3 pm (GMT+1). For further information see www.artimplant.com. * Figures in brackets refer to the corresponding period last year